A SERCA2 pump with an increased Ca2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 2, 2006, Pages 308-317

  Vangheluwe, Peter ^a   Tjwa, Marc ^b   Van Den Bergh, An ^a   Louch, William E ^c   Beullens, Monique ^a   Dode, Leonard ^a   Carmeliet, Peter ^b   Kranias, Evangelia ^d   Herijgers, Paul ^a   Sipido, Karin R ^c   Raeymaekers, Luc ^a   Wuytack, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Beta adrenergic stimulation; Calcium cycling; Cardiac hypertrophy anddysfunction; Gene targeted mice; Phospholamban; Sarcoplasmic reticulum Ca2+ ATPase (SERCA)

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM ION; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM ADENOSINE TRIPHOSPHATASE (CALCIUM); SARCOPLASMIC RETICULUM ADENOSINE TRIPHOSPHATASE (CALCIUM) 2A; SARCOPLASMIC RETICULUM ADENOSINE TRIPHOSPHATASE (CALCIUM) 2B; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; BINDING AFFINITY; CALCIUM BINDING; CELL STRUCTURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EXERCISE; HEART DEATH; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE HYPERTROPHY; LIFESPAN; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; STRESS; WILD TYPE;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CARDIOMEGALY; CROSSES, GENETIC; HEART FAILURE, CONGESTIVE; ION TRANSPORT; LONGEVITY; MICE; MICE, KNOCKOUT; PHYSICAL CONDITIONING, ANIMAL; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; STRESS; SUBSTRATE SPECIFICITY;

EID: 33746080411     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.05.014     Document Type: Article

References (32)

1. 2+ homeostasis and cardiac contractility. J Mol Cell Cardiol 33 (2001) 1053-1063
2. 2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 38 (2005) 291-302
3. MacLennan D.H., and Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev, Mol Cell Biol 4 (2003) 566-577
4. Dash R., Kadambi V., Schmidt A.G., Tepe N.M., Biniakiewicz D., Gerst M.J., et al. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103 (2001) 889-896
5. Schmitt J.P., Kamisago M., Asahi M., Li G.H., Ahmad F., Mende U., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299 (2003) 1410-1413
6. del Monte F., and Hajjar R.J. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546 (2003) 49-61
7. Minamisawa S., Hoshijima M., Chu G., Ward C.A., Frank K., Gu Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99 (1999) 313-322
8. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., and Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 105 (2002) 904-907
9. Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M.O., Gu Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8 (2002) 864-871
10. Song Q., Schmidt A.G., Hahn H.S., Carr A.N., Frank B., Pater L., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111 (2003) 859-867
11. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111 (2003) 869-876
12. 2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 89 (2001) 838-846
13. 2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses. J Biol Chem 278 (2003) 47877-47889
14. 2+ transport ATPase isoforms SERCA2a and SERCA2b are targeted to the same sites in the murine heart. Cell Calcium 34 (2003) 457-464
15. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75 (1994) 401-409
16. 2+-ATPase with sequence-specific antibodies. Evidence for plasticity of the c-terminal domain. J Biol Chem 272 (1997) 29015-29032
17. 2+-pump isoforms and of phospholamban in pig smooth-muscle tissues. Biochem J 271 (1990) 649-653
18. 2+-transport ATPase. Biochem J 264 (1989) 765-769
19. 1Ca2 transition. J Biol Chem 272 (1997) 30244-30253
20. Georgakopoulos D., Mitzner W.A., Chen C.H., Byrne B.J., Millar H.D., Hare J.M., et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 274 (1998) H1416-H1422
21. 2+ loads only. Circ Res 92 (2003) 881-887
22. Desai K.H., Schauble E., Luo W., Kranias E., and Bernstein D. Phospholamban deficiency does not compromise exercise capacity. Am J Physiol 276 (1999) H1172-H1177
23. 2+ pumps and their modulation by phospholamban. Biochem J 286 Pt 2 (1992) 591-595
24. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002) 1387-1393
25. Georgakopoulos D., and Kass D. Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart. J Physiol 534 (2001) 535-545
26. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94 (1997) 8121-8126
27. 2+ homeostasis and cardiomyocyte function. J Biol Chem 275 (2000) 38073-38080
28. 2+ handling in a calcineurin transgenic model of heart failure. Cardiovasc Res 54 (2002) 105-106
29. 2+ uptake but decreases myocyte shortening. Circulation 110 (2004) 3553-3559
30. Wu W.C., Bhavsar J.H., Aziz G.F., and Sadaniantz A. An overview of stress echocardiography in the study of patients with dilated or hypertrophic cardiomyopathy. Echocardiography 21 (2004) 467-475
31. Kadambi V.J., Ponniah S., Harrer J.M., Hoit B.D., Dorn II G.W., Walsh R.A., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 97 (1996) 533-539
32. 2+-ATPase superinhibition and cardiac remodeling. Circulation 113 (2006) 995-1004